- Ç×ü ¿£Áö´Ï¾î¸µ & Ç×ü Ä¡·á ÄÁÆÛ·±½º ¾Æ½Ã¾Æ 2020 -
Ç×ü ¿ä¹ý, ´Ü¹éÁú ¿ä¹ý, Ç×ü¾à¹°°áÇÕü(ADC), ÀÌÁ߯¯À̼ºÇ×ü, ¾Ï ¸é¿ªÄ¡·áÀÇ °³¹ßÀ» °¡¼Ó½ÃŰ´Â ÃֽŠ¿¬±¸ ¼º°ú, ±â¼ú, Á¦ÈÞ »ó´ë¸¦ ¹ß°ßÇÒ ¼ö ÀÖ´Â ¾Æ½Ã¾Æ Áö¿ª À¯ÀÏÀÇ À̺¥Æ®
¼¼°è À¯¸í ¿¬±¸ÀÚ°¡ Ãֽбâ¼ú¿¡ °üÇÑ Á¤º¸ ¹× ¿¬±¸°³¹ßÀÇ ¼º°ú, ÀÓ»ó µ¥ÀÌÅ͸¦ °øÀ¯Çϸç, Â÷¼¼´ë Ä¡·áÁ¦ÀÇ »ó¾÷Àû ¼º°ø °¡¼Ó
ÄÁÆÛ·±½º ½Åû °ü·Ã ¾Ë¸²
º» ÄÁÆÛ·±½º´Â ¿¹Á¤´ë·Î °³Ãֵ˴ϴÙ.´Ü, Á¦¹Ý »çÁ¤¿¡ µû¶ó ³»¿ëÀÇ ÀϺΰ¡ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.
»ó¼¼ Á¤º¸´Â ÇöÁö¿¡¼ È®ÀÎÇØÁֽñ⠹ٶø´Ï´Ù.
¾çÇØ ºÎʵ右´Ï´Ù.
No WHO or government travel restrictions have been issued for Japan, and this event is scheduled to go ahead as planned. We will continue to monitor the situation and act on appropriate advice.
We are in continuous contact with speakers who are still committed to attending and presenting new data and science at the event, and more delegates are booking daily. Over the course of the week we will welcome over 420 attendees from a spectrum of biopharmaceutical development and production companies ready to share ideas and network!
We look forward to welcoming you in Kyoto.
¸íÈ®ÇÑ ºñÀüÀ» °¡Áø Àü¹®°¡°¡ Ãֽе¥ÀÌÅÍ ¹× ¿¬±¸ ¼º°ú ¹ßÇ¥
Â÷¼¼´ë Ä¡·áÁ¦ÀÇ »óÇ°È °¡¼ÓÀ» Áö¿øÇÏ´Â Ãֽбâ¼ú ¹× ¿¬±¸°³¹ßÀÇ ¼º°ú, ÀÓ»ó µ¥ÀÌÅÍ
Ä¡·áÁ¦ °³¹ßÀ» °¡¼Ó½ÃŰ´Â »õ·Î¿î ¹æ¹ý
- Ä¡·áÁ¦ ¼³°è¸¦ À§ÇÑ ¼¼Æ÷³» ¿î¼Û °æ·ÎÀÇ Ç¥ÀûÈ¿¡ °üÇÑ Sally WardÀÇ ¿¬±¸
- ÇÕ¼º °áÇÕ ´Ü¹éÁúÀ» ±â¹ÝÀ¸·Î ÇÑ »õ·Î¿î Ä¡·áÁ¦¿¡ °üÇÑ Shohei KoideÀÇ ¿¬±¸
- ¾ÏÄ¡·á¸¦ À§ÇÑ »õ·Î¿î ÀÌÁ߯¯À̼º ¥ã¥äT¼¼Æ÷ °ü¿©Ç×ü¿¡ °üÇÑ Lava TherapeuticsÀÇ ¿¬±¸
- Chugai°¡ ½ÃÇàÇϰí ÀÖ´Â °íÇüÁ¾¾çÀ» Ç¥ÀûÀ¸·Î ÇÑ Ç×üÀÇ Ä¡·á Áö¼ö °³¼±À» ¸ñÀûÀ¸·Î ÇÑ Ç×ü ¿£Áö´Ï¾î¸µ ºÐ¾ßÀÇ »õ·Î¿î ¿¬±¸
- Ç×ü¾à¹°°áÇÕü¿¡ ´ëÇÑ TakedaÀÇ ºñÀü : ÇÁ·Î±×·¥ÀÇ °³¿ä¿Í ÁøÃ´ »óȲ
- °íÇüÁ¾¾ç¿¡ ´ëÇÑ T¼¼Æ÷Ä¡·áÀÇ »õ·Î¿î Ç÷§ÆûÀÎ Prime CAR-T¼¼Æ÷ ±â¼ú¿¡ °üÇÑ Koji TamadaÀÇ ¿¬±¸
¿¬±¸°³¹ßÀÇ »ç·Ê ¿¬±¸¿Í »õ·Î¿î µ¥ÀÌÅÍ
- Invenra, Amgen, Argenx, Xencor, Immatics, AbbVieÀÇ »ç·Ê ¿¬±¸¿Í »õ·Î¿î µ¥ÀÌÅÍ
- Eisai°¡ ½ÃÇàÇϰí ÀÖ´Â ½Å±Ô Çן¿ì Ç×ü °³¹ßÀÇ ÁøÃ´ »óȲ
- NBE-Therapeutics°¡ °³¹ßÀ» ÁøÇàÇϰí ÀÖ´Â ¾ÈÆ®¶ó»çÀÌŬ¸° ±â¹Ý ¸é¿ª ÀÚ±Ø Ç×ü¾à¹°°áÇÕü NBE-002ÀÇ ÃֽŠÁ¤º¸
- µö·¯´× ±â¼úÀÌ °¡´ÉÇÏ°Ô ÇÏ´Â Æ÷À¯·ù ¼¼Æ÷³»¿¡¼ Ä¡·á¿ë Ç×üÀÇ ÃÖÀûÈ¿¡ °üÇÑ Sai ReddyÀÇ µ¥ÀÌÅÍ
- Genentech°¡ °³¹ßÀ» ÁøÇàÇϰí ÀÖ´Â Ç×Á¾¾ç ¸é¿ªÀ» °ÈÇÏ´Â MerTK Ç×ü ÀúÇØÁ¦
- Dainippon Sumitomo°¡ °³¹ßÇϰí ÀÖ´Â »õ·Î¿î Ç×ü¾à¹°°áÇÕü ±â¼ú·Î¼ÀÇ Antibody Intracellular Activated Drug Conjugate(AiADC)
ÄÁÆÛ·±½º ÇÏÀ̶óÀÌÆ®
- T¼¼Æ÷ ¼ö¿ëü(TCR)¿Í Ű¸Þ¶ó Ç׿ø ¼ö¿ëü(CAR)T¼¼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·áÁ¦ °³¹ßÀ» ¸ñÀûÀ¸·Î ÇÑ ¿£Áö´Ï¾î¸µ Àü·«¿¡ °üÇÑ ¿öÅ©¼¥ °³ÃÖ
- ¿¬±¸±â°ü ¹× ±â¾÷¿¡ ¼Ò¼ÓµÈ À¯¸í ¿¬±¸ÀÚÀÇ ±âÁ¶ °¿¬
- Ç×ü ¿ä¹ýÀÇ ¿¬±¸°³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ´Â ¹Ì±¹ ¹× À¯·´ ±â¾÷ÀÇ ÀÓ¿øÀÌ °¿¬ ÁøÇà
- ¹Ì°ø°³ ¿¬±¸ ¼º°ú ¹× µ¥ÀÌÅÍ ¼Ò°³ - ¿¬»çÀÇ 80%´Â »õ·Î¿î ¿¬»ç
- ÀϺ» ±³Åä¿¡¼ °³ÃÖ - ´Ù¾çÇÑ Á¶»ç¿¡¼ ¸¹Àº »ç¶÷ÀÌ ¹æ¹®ÇÏ°í ½Í´Ù°í ´äº¯ÇÑ µµ½Ã Áß Çϳª
- Àü½Ãȸ¿Í Æ÷½ºÅÍ ¼¼¼Ç È®Ãæ
Æ÷½ºÅÍ ¹ßÇ¥¸¦ ÅëÇØ ¼¼°è °¢ÁöÀÇ ÄÁÆÛ·±½º Âü°¡ÀÚ¿¡°Ô ¿¬±¸ ¼º°ú ¾îÇÊ
- ÃÊÁ¡À» ¸ÂÃá ³íÀÇ :
Æ÷½ºÅÍ ¹ßÇ¥´Â ¹ßÇ¥ÀÚ¿Í °°Àº Å׸¶ ¹× ÀÀ¿ë ºÐ¾ß¿¡ °ü½ÉÀ» °¡Áø ¿¬±¸ÀÚ¿Í ÀǰßÀ» ±³È¯ÇÒ ¼ö ÀÖ´Â ÃÖÀûÀÇ ±âȸ·Î, ¿©±â¿¡¼ÀÇ ³íÀǰ¡ ÇâÈÄ Çù¾÷ °ü°è·Î ¿¬°áµÉ °¡´É¼ºµµ ÀÖ½À´Ï´Ù. - °øÁ¤ÇÑ ºñÆò :
´Ù¸¥ ¿¬±¸ÀÚ¿ÍÀÇ ÅëÂû·Â ÀÖ´Â °øÁ¤ÇÑ ³íÀǸ¦ ÅëÇØ ÇâÈÄ ¿¬±¸¸¦ °³¼±Çϱâ À§ÇÑ ¾ÆÀ̵ð¾î¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. - ÇÁ·¹Á¨Å×ÀÌ¼Ç ½ºÅ³ÀÇ Çâ»ó :
Æ÷½ºÅÍ ¹ßÇ¥¸¦ ÅëÇØ ´Ù¾çÇÑ ¹æ¹ýÀ¸·Î °³³äÀ» ¼³¸íÇÔÀ¸·Î½á ûÁßÀÌ °¡Àå Àß ¹Þ¾ÆµéÀÌ´Â ¹æ½ÄÀÌ ¹«¾ùÀÎÁö ÆÄ¾ÇÇϰí, ½Ã°¢Àû Ç¥Çö ¹× ±¸µÎ ÇÁ·¹Á¨Å×À̼ÇÀ» ¿¬½ÀÇÒ ¼ö ÀÖ½À´Ï´Ù. - ¾ÆÀ̵ð¾î ¿¬¸¶ :
Æ÷½ºÅÍ ¹ßÇ¥´Â ¾ÆÀ̵ð¾î ´Ü°èÀÎ Ãʱ⠴ܰèÀÇ ¿¬±¸¸¦ ¼Ò°³Çϱâ À§ÇÑ ÀÌ»óÀûÀÎ ¹«´ë·Î, °°Àº ºÐ¾ßÀÇ ¿¬±¸ÀÚ¿Í ÀǰßÀ» ±³È¯ÇÔÀ¸·Î½á Å« ¼öÈ®À» °ÅµÑ ¼ö ÀÖ½À´Ï´Ù.
Æ÷½ºÅÍ ¹ßÇ¥¸¦ ÁøÇàÇϱâ À§Çؼ´Â ÄÁÆÛ·±½º Âü°¡ µî·ÏÀÌ ÇÊ¿äÇÕ´Ï´Ù. Æ÷½ºÅÍ ÃÊ·Ï Á¦Ãâ ±âÇÑÀº 2020³â 1¿ù 24ÀÏÀÔ´Ï´Ù.

°úÇÐÀÚ¹®À§¿øÈ¸¸¦ ±¸¼ºÇÏ´Â ¿ì¼ö ¿¬±¸ÀÚ
- Tomoyuki Igawa, Ph.D., CEO and Research Head, Chugai Pharmabody Research Pte. Ltd., Singapore
- Qing Li, Ph.D., Scientist I, Medimmune, USA
- Sai Reddy, Ph.D., Assistant Professor, ETH Zurich,Switzerland
- Jijie Gu, Ph.D., Chief Scientific Officer and Executive Vice President,
WuXi Biologics, China - Chengbin Wu, Ph.D., Chief Executive Officer, Shanghai EpimAb Biotherapeutics Inc., China
- Yong-Sung Kim, Ph.D., Professor, Departments of Molecular Science and Technology, and Applied Chemistry and Biological Engineering,Ajou University, South Korea
- Karthik Viswanathan, Director, Research, Visterra, Inc., USA
- Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica, USA
¾Æ½Ã¾Æ Áö¿ª ÁÖ¿ä ¹ÙÀ̾î¿ÍÀÇ ³×Æ®¿öÅ·
»ç¾÷°³¹ßÀÇ »õ·Î¿î ±âȸ ȹµæ¿¡ ÁßÁ¡À» µÎ¸é¼ ȸ»çÀÇ ÀÎÁöµµ¸¦ ³ôÀ̰ųª ½ÅÁ¦Ç°À» ¹ßÇ¥ÇÏ°í ½Í¾îÇÏ´Â ±â¾÷À» À§ÇÑ ¸ÂÃãÇü ¼Ö·ç¼ÇÀÌ ¸¶·ÃµÇ¾î ÀÖÀ¸¸ç, °³º° ±â¾÷ÀÇ ¸ñÇ¥ ´Þ¼ºÀ» Áö¿øÇÕ´Ï´Ù.
